Business Description
Biomarin Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US09061G1013
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.95 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | 3.05 | |||||
Interest Coverage | 10.68 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.81 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.2 | |||||
3-Year EBITDA Growth Rate | 54.8 | |||||
3-Year EPS without NRI Growth Rate | -21.6 | |||||
3-Year Book Growth Rate | 5.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 43.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 15.93 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.47 | |||||
9-Day RSI | 66.47 | |||||
14-Day RSI | 56.05 | |||||
6-1 Month Momentum % | -11.82 | |||||
12-1 Month Momentum % | -9.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.74 | |||||
Quick Ratio | 1.7 | |||||
Cash Ratio | 0.96 | |||||
Days Inventory | 735.25 | |||||
Days Sales Outstanding | 90.13 | |||||
Days Payable | 206.4 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.23 | |||||
Operating Margin % | 7.17 | |||||
Net Margin % | 8.31 | |||||
FCF Margin % | 6.67 | |||||
ROE % | 4.22 | |||||
ROA % | 3.07 | |||||
ROIC % | 2.99 | |||||
ROC (Joel Greenblatt) % | 11.19 | |||||
ROCE % | 4.4 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 75.41 | |||||
Forward PE Ratio | 30.3 | |||||
PE Ratio without NRI | 42.29 | |||||
PS Ratio | 6.31 | |||||
PB Ratio | 3.02 | |||||
Price-to-Tangible-Book | 3.33 | |||||
Price-to-Free-Cash-Flow | 95.38 | |||||
Price-to-Operating-Cash-Flow | 55.61 | |||||
EV-to-EBIT | 60.53 | |||||
EV-to-Forward-EBIT | 40.56 | |||||
EV-to-EBITDA | 42.79 | |||||
EV-to-Forward-EBITDA | 31.07 | |||||
EV-to-Revenue | 6.22 | |||||
EV-to-Forward-Revenue | 5.58 | |||||
EV-to-FCF | 94.18 | |||||
Price-to-Projected-FCF | 3.96 | |||||
Price-to-Median-PS-Value | 0.59 | |||||
Price-to-Graham-Number | 2.5 | |||||
Price-to-Net-Current-Asset-Value | 12.92 | |||||
Earnings Yield (Greenblatt) % | 1.65 | |||||
FCF Yield % | 1.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Biomarin Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,283.642 | ||
EPS (TTM) (€) | 0.989 | ||
Beta | 0.19 | ||
Volatility % | 21.68 | ||
14-Day RSI | 56.05 | ||
14-Day ATR (€) | 1.247735 | ||
20-Day SMA (€) | 71.171 | ||
12-1 Month Momentum % | -9.9 | ||
52-Week Range (€) | 68.18 - 90.16 | ||
Shares Outstanding (Mil) | 189.88 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Biomarin Pharmaceutical Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Biomarin Pharmaceutical Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Biomarin Pharmaceutical Inc Frequently Asked Questions
What is Biomarin Pharmaceutical Inc(WBO:BMRN)'s stock price today?
When is next earnings date of Biomarin Pharmaceutical Inc(WBO:BMRN)?
Does Biomarin Pharmaceutical Inc(WBO:BMRN) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |